Menu Search
Equities

Takeda Pharmaceutical Co Ltd

TKDA:DUS

Takeda Pharmaceutical Co Ltd

Actions
  • Price (EUR)15.20
  • Today's Change0.20 / 1.33%
  • Shares traded0.00
  • 1 Year change+13.43%
  • Beta--
Data delayed at least 15 minutes, as of Mar 27 2023 15:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in USD (TTM)30.18bn
  • Net income in USD2.10bn
  • Incorporated1925
  • Employees47.35k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4502:TYO since
announced		Transaction
value
Nimbus Lakshmi IncDeal completed13 Dec 202213 Dec 2022Deal completed6.02%6.00bn
Shionogi & Co Ltd-Intuniv & Vyvanse Manufacturing & Sales BusinessAnnounced31 Oct 202231 Oct 2022Announced11.99%--
Data delayed at least 20 minutes, as of Mar 27 2023 07:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.